Crescendo Biologics Appoints Matthew Roe as Chief Business Officer

CAMBRIDGE, England, June 21, 2011 -

Crescendo Biologics Limited (Crescendo) today announces the
appointment of Matthew Roe as Chief Business Officer. Matthew joins
Crescendo from Genzyme Corporation where he was Senior Director,
Business Development & Licensing.

During a 23-year career at Genzyme, Matthew was active in
licensing, alliance management, acquisition, divestment, and sales
and marketing, and saw the corporation develop from an
entrepreneurial start-up to a leading multi-national biotechnology
company. He negotiated and managed multiple agreements for drug
delivery technologies in the USA, Europe and Japan and was also a
core team member on the divestment of Genzyme’s Pharmaceuticals
business.

Mike Romanos, CEO of Crescendo said: “Matthew’s track record in
business development speaks for itself. He has an exceptional depth
of experience in business strategy and in implementing agreements
across multiple territories. I look forward to working with him as
we build on the significant advances we have made at Crescendo and
position the Company to deliver real value from its world class,
proprietary technology platforms.”

Matthew Roe, CBO of Crescendo said: “The monoclonal antibody
market is rapidly growing and continues to be a major focus for the
pharma industry. Companies are searching for new platforms and
approaches, particularly in the area of antibody fragments.
Crescendo’s technology platform, IP and insight create a strong
foundation from which to make a significant impact in the field and
I am delighted to be joining the Company’s management team as it
seeks to grow to become a leader in next-generation antibody
therapeutics.”

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody
fragment technologies to the development of new targeted
therapeutics. The Crescendo transgenic mouse platform under
development has the potential to rapidly and predictably generate
high-affinity human heavy chain antibodies that readily yield
V_H fragments that have no requirement for humanisation.
This is combined with a powerful in vitro ribosome display
technology which offers significant advantages over existing
approaches in antibody optimisation. V_H fragments
provide great flexibility as a starting point for the development
of new targeted therapeutics combining the specificity and binding
affinity of antibodies with certain desirable characteristics of
small molecules.

Crescendo’s technologies were invented by scientists at the
Babraham Institute, Cambridge (UK). The Company has raised £4.5
million in seed funding from leading life sciences investors,
Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow
Seed Fund also participating.
 www.crescendobiologics.com

Contacts

Mike Romanos/Amanda Bettison
Crescendo Biologics
Tel: +44(0)1223-497140
Email: mromanos/abettison@crescendobiologics.com

Chris Gardner
Citigate Dewe Rogerson
Tel: +44(0)207-638-9571
Email: chris.gardner@citigatedr.co.uk

.